Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

127.84 +2.03 (+1.61%)
Streaming Delayed Price Updated: 12:30 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dexcom Inc

< Previous 1 2 3 4 Next >
Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians
From Dexcom, Inc.
Via Business Wire
Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More
From Dexcom, Inc.
Via Business Wire
Dexcom Updates Long-Range Financial Targets
From DexCom, Inc.
Via Business Wire
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next. 
Via MarketBeat
DarioHealth is an AI-Powered Digital Therapeutics Play
DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Dexcom to Host Investor Day on June 23, 2023
From DexCom, Inc.
Via Business Wire
Dexcom Announces Upcoming Conference Presentation
From DexCom, Inc.
Via Business Wire
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
From DexCom, Inc.
Via Business Wire
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
From DexCom, Inc.
Via Business Wire
Dexcom Reports First Quarter 2023 Financial Results
From DexCom, Inc.
Via Business Wire
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB
From Dexcom, Inc.
Via Business Wire
3 Medtech Companies with Higher Future Share Prices
The analysts see normalization and growth for the med tech industry and have started picking their favorites for 2023 and beyond. 
Via MarketBeat
Diversified Abbott Laboratories Could Reverse And Move Higher
Abbott Laboratories reported a solid quarter driven by gains in the core business that are accelerating as COVID sales decline. 
Via MarketBeat
Exposures COVID-19
Healthcare Innovation Drives Medical Device Makers To New Highs
Medical products makers Stryker and Boston Scientific are rallying to all-time highs, while sector peer DexCom is forming a constructive base. 
Via MarketBeat
Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin
From Dexcom, Inc.
Via Business Wire
Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
DexCom Comments on SVB Relationship
From DexCom, Inc.
Via Business Wire
Dexcom Announces Upcoming Conference Presentations
From DexCom, Inc.
Via Business Wire
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
From Dexcom, Inc.
Via Business Wire
Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From DexCom, Inc.
Via Business Wire
InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Expanding Platform to Integrate Market-Leading CGM Data
Via Investor Brand Network
Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System
From DexCom, Inc.
Via Business Wire
Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Insulet Has Potential To Gain More Than Analysts Are Forecasting
Even as it pulled back with the broader market Tuesday, insulin pump maker Insulet found support along its 50-day line and remained in possible buy range. 
Via MarketBeat
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
From DexCom, Inc.
Via Business Wire
Dexcom Appoints Teri Lawver as Chief Commercial Officer
From DexCom, Inc.
Via Business Wire
Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference
From DexCom, Inc.
Via Business Wire
Can FDA Approval Bolster DexCom, Inc.?
Dexcom is relying on the interest and sales of its new continuous glucose monitor--which recently received FDA approval--to boost revenue (and stock value). 
Via MarketBeat
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.